Work

268. CD19-Targeted Normal and CLL Patient T Cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo

Year: 2006

Type: article

Abstract: In order to conduct a clinical trial of adoptive therapy with genetically modified T cells in patients with CLL, we are investigating the feasibility of ex vivo T cell transduction and expansion using Xcyte™ Dynabeads® to generate sufficient numbers of biologically active tumor-reactive T cells. T cells are genetically modified to express 19-28z chimeric antigen receptor (CAR). The 19-28z CAR is derived from a single chain fragment length murine antibody specific to the human CD19 antigen expressed on CLL tumor cells, fused to the transmembrane and cytoplasmic domains of the human CD28 co-stimulatory receptor and the cytoplasmic domain of the CD3ζ chain of the human T cell receptor.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2006.08.322

Authors: J. Stefanski, R. Brentjens, D. Hollyman, M. Bonyhadi, M. Sadelain, I. Rivière

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500